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Abstract 
At the age of 83, a woman presented with an
extremely rare cancer, basal cell adenocarcino-
ma  (BCAC)  of  the  supraglottic  larynx.
Pathology revealed a stage IVA tumor, patho-
logical stage T4N0M0. She was treated with
surgery  and  did  not  receive  any  adjuvant
chemotherapy or radiation therapy.  At the age
of  93,  during  a  routine  examination,  the
patient was found to have palpable adenopathy
and  underwent  a  fine  needle  aspiration  in
June 2010. Pathology revealed similar histo-
logic characteristics of her 2001 BCAC diagno-
sis, and further IHC stains revealed positive
estrogen receptor staining.
Case Report
We report a case of a 83-years-old woman
presented  with  a  basal  cell  adenocarcinoma
(BCAC) of the supraglottic larynx and dyspha-
gia to solids and liquids. Evaluation revealed a
malignant mass in the supraglottic larynx. 
Past  medical  history  includes  surgically
treated lobular breast cancer in the 1980’s fol-
lowed by five years of adjuvant tamoxifen, hys-
terectomy in the 1980’s for non-malignant con-
dition, left hip rod placed in 2009 for fracture
from a fall, and several basal cell cancers of the
skin which were removed.
She  underwent  a  complete  laryngectomy,
tracheopharyngeal myotomy and partial glos-
sectomy in 2002. Pathology revealed a 3.2¥2.0
¥1.5 cm polymorphous low grade tumor of sali-
vary gland origin consistent with BCAC. The
tumor was a stage IVA BCAC of the supraglot-
tic larynx, pT4N0M0. She did not receive any
adjuvant  chemotherapy  or  radiation  therapy
and was followed for several years by physical
examination and imaging. 
In March 2010, at the age of 93, during a
routine examination, she was found to have
palpable adenopathy. At this point, she did not
exhibit any additional symptoms related to the
enlarged  lymph  nodes.  A  PET/CT  study
revealed a 3 cm nodal mass with a peak SUV of
9.3 was found in the anterior left neck, below
the hyoid. Another mass was found lower in
the anterior right neck, measuring 2.7 cm in
diameter  and  having  a  peak  SUV  of  9.6.
Ultrasound in May 2010 revealed a left neck
mass measuring 2.9¥1.9¥ 2.3 cm and the right
neck  mass  was  measuring  3.1¥2.1¥2.45  cm
and a left lower cervical chain mass was meas-
ured at 1.8¥1.3¥1.8 cm.
The patient underwent a fine needle core
biopsy in June 2010. Pathology revealed simi-
lar histologic characteristics of her 2001 BCAC
diagnosis. Figure 1 shows the tumor stained
with  hematoxylin  and  eosin  (H&E).  The
patient was not considered an optimal candi-
date  for  surgery  and/or  radiotherapy  due  to
high risk for morbidity and patient’s prefer-
ence. Additional staining of this core biopsy
specimen  revealed,  estrogen  receptor  (ER)
(Figure 2), CK7, and GCDFP-15 positivity, and
negative  staining  for  progesterone  receptor
(PR) (Figure 3), CK20 and TTF-1. ER and PR
staining were requested to see if there might
be a potential drug that could target this tumor
as a palliative therapy with a relatively lower
risk of morbidity than other systemic thera-
pies. 
Based  on  the  ER  staining  of  the  tumor
(Table 1), the patient started oral tamoxifen 20
mg daily in July 2010, and four weeks later,
demonstrated  by  physical  exam  an  approxi-
mate 50% decrease in the size of her bilateral
submandibular  and  anterior  cervical  lym-
phadenopathy.  At  subsequent  monthly  visits,
there has not been appreciable change in the
size of these lymph nodes. 
Discussion
An  extremely  rare  neoplasm,  BCAC,  was
first described in 1978.1 BCAC is noted to occur
in adults aged 60 and older,2 and usually car-
ries with it a favorable prognosis, and is cate-
gorized as a low-grade tumor with slow pro-
gression.3
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Figure 1. Fine-needle core biopsy specimen
taken during ultrasound-guided biopsy of
left  neck  lymph  node  stained  for  hema-
toxylin and eosin (H&E) at 10X magnifi-
cation. Higher magnification (40X) is dis-
played in the lower right quadrant. 
Figure 2. Fine-needle core biopsy specimen
(10X  magnification)  taken  from  the  left
neck stained for ER, showing 15% positive
staining.  Higher  magnification  (40X)  is
displayed in the lower right quadrant.
Figure 3. Fine-needle core biopsy specimen
taken from the left neck stained for PR,
showing  absence  of  positive  staining
tumor cells at 40X magnification.[page 170] [Rare Tumors 2011; 3:e55]
Approximately  90%  of  the  known  BCAC
cases involve the parotid gland,4-6 followed in
frequency  by  the  submandibular  and  minor
salivary  glands.7 Local  excision  with  tumor-
free margins is the standard first-line treat-
ment.  Recurrence  is  common,  occurring  in
37% of cases with a median follow up of 36
months.2 Distant  metastasis  is  uncommon,
occurring  in  only  4%  of  cases,  while
local/regional lymph node metastasis occurs in
8% of cases.2
There remains no standard systemic treat-
ment for BCAC. Because she was not an opti-
mal  surgical  or  radiotherapy  candidate  and
patient preference for palliative therapy with
lower risk of morbidity, we requested tumor
staining  for  ER  and  PR  to  see  if  tamoxifen
might  be  a  reasonable  palliative  therapy.
Indeed, her tumor demonstrated ER positive
staining  and  tamoxifen  was  initiated.  The
patient has not experienced significant toxici-
ty and has shown response with clinical evi-
dence of stable disease. When surgery and/or
radiotherapy are not feasible for the treatment
of recurrent BCAC, staining for ER may reveal
a  potential  therapy  with  an  adequate  side
effect and safety profile.
References
1. Klima M, Wolfe K, Johnson PE. Basal Cell
tumors  of  the  parotid  gland.  Arch
Otolaryngol 1978;104:111-6
2. Muller S, Barnes L. Basal cell adenocarci-
noma  of  the  salivary  glands  -  Report  of
seven cases and review of the literature.
Cancer 1996;78:2471-7.
3. Barnes L, Eveson JW, Reichart P, Sidransky
D. Pathology and Genetics of Tumours of
the  Head  and  Neck.  World  Health
Organization  Classification  of  Tumours.
IARC Press. Lyon, France: 2005.
4. Ellis GL, Wiscovitch JG. Basal cell adeno-
carcinoma  of  the  major  salivary  glands.
Oral  Surg  Oral  Me  Oral  Pathol
1990;69:461-9.
5. González-Garcia R, Nam-Cha SH, Muñoz-
Guerra  MF,  Gamallo-Amat  C.  Basal  cell
adenoma of the parotid gland: case report
and  review  of  the  literature.  Med  Oral
Patol Oral Cir Bucal 2006;11:E206-9.
6. Franzen A, Koegel K, Knieriem HJ, Pfaltz
M.  Basal  cell  adenocarcinoma  of  the
parotid  gland:  a  rare  tumor  entity.  Case
report and review of the literature. HNO
1998;46:821-5.
7. Ellis GL, Auclair PL. Tumors of the Salivary
Glands.  Atlas  of  Tumor  Pathology,  3rd
series,  fascicle  17  Washington,  D.C.:
Armed Forces Institute of Pathology 1996.
pp 257-267.
Case Report
Table 1. Immunohistochemistry results and potential treatment.
Positive immuanohistochemistry Conclusion % staining Potential 
staining  positive agent
Estrogen receptors Positive 15% Tamoxifen
Progesterone receptors Negative 0% Not applicable